This report focuses on the World Health Organization's (WHO) Emergency Use Listing (EUL) of authorized vaccines as of August 16, 2021. Currently six vaccines are authorised for emergency use: BNT162b2/COMIRNATY (Pfizer-BioNTech, USA), Spikevax/Moderna COVID-19 Vaccine/ mRNA-1273 (Moderna, USA), Vaxzevria/ChAdOx1 nCoV-19/AZD1222/Covishield (AstraZeneca/Oxford, UK, India), Janssen Covid-19 vaccine/Johnson & Johnson (Janssen, USA), Sinopharm/BBIBP-CorV (China), and Sinovac/CoronaVac (China). This report provides a condensed summary concerning vaccine efficacy, safety, protection against variants, and further important information for each vaccine, in the form of a synoptic table. The information and data in this synoptic table was extracted from phase III clinical trials and, in some cases, from observational studies. This report particularly focuses on heterologous vaccination schedules (e.g., mixing ChAdOx1 and mRNA vaccines), Sinopharm/ BBIBP-CorV and Sinovac/ CoronaVac's inactivated vaccines, and provides the latest updates and information on children and adolescent vaccinations.